Eden Research PLC
LSE:EDEN
Intrinsic Value
Eden Research Plc offers sustainable solutions for crop protection, animal health and consumer products in the United Kingdom and rest of Europe. [ Read More ]
The intrinsic value of one EDEN stock under the Base Case scenario is 0.77 GBX. Compared to the current market price of 4.85 GBX, Eden Research PLC is Overvalued by 84%.
Valuation Backtest
Eden Research PLC
Run backtest to discover the historical profit from buying and selling EDEN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Eden Research PLC
Current Assets | 2.7m |
Cash & Short-Term Investments | 492.8k |
Receivables | 1.5m |
Other Current Assets | 750.6k |
Non-Current Assets | 4.4m |
Long-Term Investments | 305.1k |
PP&E | 432.3k |
Intangibles | 3.6m |
Other Non-Current Assets | -10 |
Current Liabilities | 2m |
Accounts Payable | 1.2m |
Accrued Liabilities | 475.7k |
Other Current Liabilities | 310.2k |
Non-Current Liabilities | 183.4k |
Long-Term Debt | 147.8k |
Other Non-Current Liabilities | 35.6k |
Earnings Waterfall
Eden Research PLC
Revenue
|
1.9m
GBP
|
Cost of Revenue
|
-1.1m
GBP
|
Gross Profit
|
848.5k
GBP
|
Operating Expenses
|
-3.3m
GBP
|
Operating Income
|
-2.5m
GBP
|
Other Expenses
|
-4.6m
GBP
|
Net Income
|
-7.1m
GBP
|
Free Cash Flow Analysis
Eden Research PLC
What is Free Cash Flow?
EDEN Profitability Score
Profitability Due Diligence
Eden Research PLC's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Eden Research PLC's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
EDEN Solvency Score
Solvency Due Diligence
Eden Research PLC's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Score
Eden Research PLC's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EDEN Price Targets Summary
Eden Research PLC
According to Wall Street analysts, the average 1-year price target for EDEN is 20.4 GBX with a low forecast of 20.2 GBX and a high forecast of 21 GBX.
Shareholder Return
EDEN Price
Eden Research PLC
Average Annual Return | -12.6% |
Standard Deviation of Annual Returns | 35.62% |
Max Drawdown | -84% |
Market Capitalization | 25.9m GBX |
Shares Outstanding | 533 352 992 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Eden Research Plc offers sustainable solutions for crop protection, animal health and consumer products in the United Kingdom and rest of Europe. The company is headquartered in Oxford, Oxfordshire and currently employs 11 full-time employees. The company went IPO on 2012-05-11. The firm develops and supplies biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries. Its products are formulated with terpene ingredients, which are based on natural plant defense metabolites. The Company’s products include Mevalone and Cedroz. Mevalone is a foliar bio-fungicide, which is focused on diseases affecting grapes, and other fruit and vegetable crops. Cedroz is a bionematicide that targets free living nematodes, which are parasitic worms that affect a range of fruit and vegetable crops globally. The Company’s subsidiary is TerpeneTech (Ireland) Limited.
Contact
IPO
Employees
Officers
The intrinsic value of one EDEN stock under the Base Case scenario is 0.77 GBX.
Compared to the current market price of 4.85 GBX, Eden Research PLC is Overvalued by 84%.